Association of PDCD1 gene markers with susceptibility to thyroid cancer
Purpose PD-1 receptor is a co-signaling molecule with an important role in regulation of T-lymphocyte activity. Correlation between PD-1 gene (PDCD1) polymorphisms and some immune-related diseases has been reported before. In current study, we aimed to investigate the association of PD-1 polymorphis...
Gespeichert in:
| Veröffentlicht in: | Journal of endocrinological investigation 2017-05, Vol.40 (5), p.481-486 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 486 |
|---|---|
| container_issue | 5 |
| container_start_page | 481 |
| container_title | Journal of endocrinological investigation |
| container_volume | 40 |
| creator | Haghshenas, M. R. Dabbaghmanesh, M. H. Miri, A. Ghaderi, A. Erfani, N. |
| description | Purpose
PD-1 receptor is a co-signaling molecule with an important role in regulation of T-lymphocyte activity. Correlation between PD-1 gene (PDCD1) polymorphisms and some immune-related diseases has been reported before. In current study, we aimed to investigate the association of PD-1 polymorphisms at positions +7146 G/A (PD-1.3) and +7785 C/T (PD-1.5), as well as the emerged haplotypes with susceptibility to thyroid carcinoma.
Methods
One hundred five patients with confirmed thyroid cancer and 160 healthy individuals as control group were enrolled. Genotypes were identified using PCR–RFLP and nested PCR–RFLP methods. Results were analyzed by Arlequin and SPSS software packages.
Results
Analysis revealed a significant increase in the frequency of PD-1.5 mutant T allele and heterozygous CT genotype in patients with thyroid cancer in comparison with controls [79 (37.7%) vs. 71 (22.2%), and 51 (48.6%) vs. 51 (31.9%),
p
= 0.0001 and
p
= 0.009, receptively]. CC genotype at this position observed to be significantly higher among controls than the patients [99 (61.9%) vs. 40 (38.1%),
p
= 0.0002]. There were no significant differences in the frequencies of genotypes and alleles at locus PD-1.3 between patients and control group. Despite this, GT haplotype emerged from both positions (PD-1.3 G and PD-1.5 T) has also been observed with significant increased frequency between patients and controls [70 (36.8%) vs. 71 (22.2%),
p
= 0.0005].
Conclusion
As the first study to investigate two mentioned polymorphisms in thyroid cancer, current study confirmed the association of PD-1.5 C/T polymorphism and a haplotype resulted from both loci, PD-1.3 and PD-1.5, with susceptibility of Iranians to thyroid cancer. |
| doi_str_mv | 10.1007/s40618-016-0579-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1852661892</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1852661892</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-eb3daa8fb99092941ce8920f32a471239abd1fccb5514660bc82d03a5b3406183</originalsourceid><addsrcrecordid>eNp1kE9LwzAYh4Mobk4_gBcJePFSzZ-2SY5j0ykM9KDnkKbpltk1M2mRfXszO2UInhLI8_7y_h4ALjG6xQixu5CiHPME4TxBGRNJdgSGmBGUcMrz44P7AJyFsEKIMsrZKRgQJlKKcjoEs3EITlvVWtdAV8GX6WSK4cI0Bq6Vfzc-wE_bLmHogjab1ha2tu0Wtg62y613toRaNdr4c3BSqTqYi_05Am8P96-Tx2T-PHuajOeJpoy0iSloqRSvCiGQICLF2nBBUEWJShkmVKiixJXWRZbhNM9RoTkpEVVZQb-70hG46XM33n10JrRybeNmda0a47ogMc9IHkFBInr9B125zjdxu0hxFutzRiOFe0p7F4I3ldx4G6tvJUZyZ1n2lmW0LHeWZRZnrvbJXbE25e_Ej9YIkB4I8alZGH_w9b-pX2abheA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1887063873</pqid></control><display><type>article</type><title>Association of PDCD1 gene markers with susceptibility to thyroid cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Haghshenas, M. R. ; Dabbaghmanesh, M. H. ; Miri, A. ; Ghaderi, A. ; Erfani, N.</creator><creatorcontrib>Haghshenas, M. R. ; Dabbaghmanesh, M. H. ; Miri, A. ; Ghaderi, A. ; Erfani, N.</creatorcontrib><description>Purpose
PD-1 receptor is a co-signaling molecule with an important role in regulation of T-lymphocyte activity. Correlation between PD-1 gene (PDCD1) polymorphisms and some immune-related diseases has been reported before. In current study, we aimed to investigate the association of PD-1 polymorphisms at positions +7146 G/A (PD-1.3) and +7785 C/T (PD-1.5), as well as the emerged haplotypes with susceptibility to thyroid carcinoma.
Methods
One hundred five patients with confirmed thyroid cancer and 160 healthy individuals as control group were enrolled. Genotypes were identified using PCR–RFLP and nested PCR–RFLP methods. Results were analyzed by Arlequin and SPSS software packages.
Results
Analysis revealed a significant increase in the frequency of PD-1.5 mutant T allele and heterozygous CT genotype in patients with thyroid cancer in comparison with controls [79 (37.7%) vs. 71 (22.2%), and 51 (48.6%) vs. 51 (31.9%),
p
= 0.0001 and
p
= 0.009, receptively]. CC genotype at this position observed to be significantly higher among controls than the patients [99 (61.9%) vs. 40 (38.1%),
p
= 0.0002]. There were no significant differences in the frequencies of genotypes and alleles at locus PD-1.3 between patients and control group. Despite this, GT haplotype emerged from both positions (PD-1.3 G and PD-1.5 T) has also been observed with significant increased frequency between patients and controls [70 (36.8%) vs. 71 (22.2%),
p
= 0.0005].
Conclusion
As the first study to investigate two mentioned polymorphisms in thyroid cancer, current study confirmed the association of PD-1.5 C/T polymorphism and a haplotype resulted from both loci, PD-1.3 and PD-1.5, with susceptibility of Iranians to thyroid cancer.</description><identifier>ISSN: 1720-8386</identifier><identifier>ISSN: 0391-4097</identifier><identifier>EISSN: 1720-8386</identifier><identifier>DOI: 10.1007/s40618-016-0579-5</identifier><identifier>PMID: 27943063</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adenocarcinoma, Follicular - blood ; Adenocarcinoma, Follicular - genetics ; Adenocarcinoma, Follicular - pathology ; Adenocarcinoma, Papillary - blood ; Adenocarcinoma, Papillary - genetics ; Adenocarcinoma, Papillary - pathology ; Adult ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Case-Control Studies ; Endocrinology ; Female ; Follow-Up Studies ; Haplotypes ; Humans ; Immune response ; Immune system ; Lymphocytes T ; Male ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Neoplasm Staging ; Original Article ; Polymerase Chain Reaction ; Polymorphism, Genetic - genetics ; Polymorphism, Restriction Fragment Length ; Prognosis ; Programmed Cell Death 1 Receptor - blood ; Programmed Cell Death 1 Receptor - genetics ; Thyroid Neoplasms - blood ; Thyroid Neoplasms - genetics ; Thyroid Neoplasms - pathology</subject><ispartof>Journal of endocrinological investigation, 2017-05, Vol.40 (5), p.481-486</ispartof><rights>Italian Society of Endocrinology (SIE) 2016</rights><rights>Copyright Springer Science & Business Media 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-eb3daa8fb99092941ce8920f32a471239abd1fccb5514660bc82d03a5b3406183</citedby><cites>FETCH-LOGICAL-c372t-eb3daa8fb99092941ce8920f32a471239abd1fccb5514660bc82d03a5b3406183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40618-016-0579-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40618-016-0579-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27943063$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haghshenas, M. R.</creatorcontrib><creatorcontrib>Dabbaghmanesh, M. H.</creatorcontrib><creatorcontrib>Miri, A.</creatorcontrib><creatorcontrib>Ghaderi, A.</creatorcontrib><creatorcontrib>Erfani, N.</creatorcontrib><title>Association of PDCD1 gene markers with susceptibility to thyroid cancer</title><title>Journal of endocrinological investigation</title><addtitle>J Endocrinol Invest</addtitle><addtitle>J Endocrinol Invest</addtitle><description>Purpose
PD-1 receptor is a co-signaling molecule with an important role in regulation of T-lymphocyte activity. Correlation between PD-1 gene (PDCD1) polymorphisms and some immune-related diseases has been reported before. In current study, we aimed to investigate the association of PD-1 polymorphisms at positions +7146 G/A (PD-1.3) and +7785 C/T (PD-1.5), as well as the emerged haplotypes with susceptibility to thyroid carcinoma.
Methods
One hundred five patients with confirmed thyroid cancer and 160 healthy individuals as control group were enrolled. Genotypes were identified using PCR–RFLP and nested PCR–RFLP methods. Results were analyzed by Arlequin and SPSS software packages.
Results
Analysis revealed a significant increase in the frequency of PD-1.5 mutant T allele and heterozygous CT genotype in patients with thyroid cancer in comparison with controls [79 (37.7%) vs. 71 (22.2%), and 51 (48.6%) vs. 51 (31.9%),
p
= 0.0001 and
p
= 0.009, receptively]. CC genotype at this position observed to be significantly higher among controls than the patients [99 (61.9%) vs. 40 (38.1%),
p
= 0.0002]. There were no significant differences in the frequencies of genotypes and alleles at locus PD-1.3 between patients and control group. Despite this, GT haplotype emerged from both positions (PD-1.3 G and PD-1.5 T) has also been observed with significant increased frequency between patients and controls [70 (36.8%) vs. 71 (22.2%),
p
= 0.0005].
Conclusion
As the first study to investigate two mentioned polymorphisms in thyroid cancer, current study confirmed the association of PD-1.5 C/T polymorphism and a haplotype resulted from both loci, PD-1.3 and PD-1.5, with susceptibility of Iranians to thyroid cancer.</description><subject>Adenocarcinoma, Follicular - blood</subject><subject>Adenocarcinoma, Follicular - genetics</subject><subject>Adenocarcinoma, Follicular - pathology</subject><subject>Adenocarcinoma, Papillary - blood</subject><subject>Adenocarcinoma, Papillary - genetics</subject><subject>Adenocarcinoma, Papillary - pathology</subject><subject>Adult</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Case-Control Studies</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Haplotypes</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Neoplasm Staging</subject><subject>Original Article</subject><subject>Polymerase Chain Reaction</subject><subject>Polymorphism, Genetic - genetics</subject><subject>Polymorphism, Restriction Fragment Length</subject><subject>Prognosis</subject><subject>Programmed Cell Death 1 Receptor - blood</subject><subject>Programmed Cell Death 1 Receptor - genetics</subject><subject>Thyroid Neoplasms - blood</subject><subject>Thyroid Neoplasms - genetics</subject><subject>Thyroid Neoplasms - pathology</subject><issn>1720-8386</issn><issn>0391-4097</issn><issn>1720-8386</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE9LwzAYh4Mobk4_gBcJePFSzZ-2SY5j0ykM9KDnkKbpltk1M2mRfXszO2UInhLI8_7y_h4ALjG6xQixu5CiHPME4TxBGRNJdgSGmBGUcMrz44P7AJyFsEKIMsrZKRgQJlKKcjoEs3EITlvVWtdAV8GX6WSK4cI0Bq6Vfzc-wE_bLmHogjab1ha2tu0Wtg62y613toRaNdr4c3BSqTqYi_05Am8P96-Tx2T-PHuajOeJpoy0iSloqRSvCiGQICLF2nBBUEWJShkmVKiixJXWRZbhNM9RoTkpEVVZQb-70hG46XM33n10JrRybeNmda0a47ogMc9IHkFBInr9B125zjdxu0hxFutzRiOFe0p7F4I3ldx4G6tvJUZyZ1n2lmW0LHeWZRZnrvbJXbE25e_Ej9YIkB4I8alZGH_w9b-pX2abheA</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Haghshenas, M. R.</creator><creator>Dabbaghmanesh, M. H.</creator><creator>Miri, A.</creator><creator>Ghaderi, A.</creator><creator>Erfani, N.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170501</creationdate><title>Association of PDCD1 gene markers with susceptibility to thyroid cancer</title><author>Haghshenas, M. R. ; Dabbaghmanesh, M. H. ; Miri, A. ; Ghaderi, A. ; Erfani, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-eb3daa8fb99092941ce8920f32a471239abd1fccb5514660bc82d03a5b3406183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adenocarcinoma, Follicular - blood</topic><topic>Adenocarcinoma, Follicular - genetics</topic><topic>Adenocarcinoma, Follicular - pathology</topic><topic>Adenocarcinoma, Papillary - blood</topic><topic>Adenocarcinoma, Papillary - genetics</topic><topic>Adenocarcinoma, Papillary - pathology</topic><topic>Adult</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Case-Control Studies</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Haplotypes</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Neoplasm Staging</topic><topic>Original Article</topic><topic>Polymerase Chain Reaction</topic><topic>Polymorphism, Genetic - genetics</topic><topic>Polymorphism, Restriction Fragment Length</topic><topic>Prognosis</topic><topic>Programmed Cell Death 1 Receptor - blood</topic><topic>Programmed Cell Death 1 Receptor - genetics</topic><topic>Thyroid Neoplasms - blood</topic><topic>Thyroid Neoplasms - genetics</topic><topic>Thyroid Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haghshenas, M. R.</creatorcontrib><creatorcontrib>Dabbaghmanesh, M. H.</creatorcontrib><creatorcontrib>Miri, A.</creatorcontrib><creatorcontrib>Ghaderi, A.</creatorcontrib><creatorcontrib>Erfani, N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of endocrinological investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haghshenas, M. R.</au><au>Dabbaghmanesh, M. H.</au><au>Miri, A.</au><au>Ghaderi, A.</au><au>Erfani, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of PDCD1 gene markers with susceptibility to thyroid cancer</atitle><jtitle>Journal of endocrinological investigation</jtitle><stitle>J Endocrinol Invest</stitle><addtitle>J Endocrinol Invest</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>40</volume><issue>5</issue><spage>481</spage><epage>486</epage><pages>481-486</pages><issn>1720-8386</issn><issn>0391-4097</issn><eissn>1720-8386</eissn><abstract>Purpose
PD-1 receptor is a co-signaling molecule with an important role in regulation of T-lymphocyte activity. Correlation between PD-1 gene (PDCD1) polymorphisms and some immune-related diseases has been reported before. In current study, we aimed to investigate the association of PD-1 polymorphisms at positions +7146 G/A (PD-1.3) and +7785 C/T (PD-1.5), as well as the emerged haplotypes with susceptibility to thyroid carcinoma.
Methods
One hundred five patients with confirmed thyroid cancer and 160 healthy individuals as control group were enrolled. Genotypes were identified using PCR–RFLP and nested PCR–RFLP methods. Results were analyzed by Arlequin and SPSS software packages.
Results
Analysis revealed a significant increase in the frequency of PD-1.5 mutant T allele and heterozygous CT genotype in patients with thyroid cancer in comparison with controls [79 (37.7%) vs. 71 (22.2%), and 51 (48.6%) vs. 51 (31.9%),
p
= 0.0001 and
p
= 0.009, receptively]. CC genotype at this position observed to be significantly higher among controls than the patients [99 (61.9%) vs. 40 (38.1%),
p
= 0.0002]. There were no significant differences in the frequencies of genotypes and alleles at locus PD-1.3 between patients and control group. Despite this, GT haplotype emerged from both positions (PD-1.3 G and PD-1.5 T) has also been observed with significant increased frequency between patients and controls [70 (36.8%) vs. 71 (22.2%),
p
= 0.0005].
Conclusion
As the first study to investigate two mentioned polymorphisms in thyroid cancer, current study confirmed the association of PD-1.5 C/T polymorphism and a haplotype resulted from both loci, PD-1.3 and PD-1.5, with susceptibility of Iranians to thyroid cancer.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>27943063</pmid><doi>10.1007/s40618-016-0579-5</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1720-8386 |
| ispartof | Journal of endocrinological investigation, 2017-05, Vol.40 (5), p.481-486 |
| issn | 1720-8386 0391-4097 1720-8386 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1852661892 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adenocarcinoma, Follicular - blood Adenocarcinoma, Follicular - genetics Adenocarcinoma, Follicular - pathology Adenocarcinoma, Papillary - blood Adenocarcinoma, Papillary - genetics Adenocarcinoma, Papillary - pathology Adult Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Case-Control Studies Endocrinology Female Follow-Up Studies Haplotypes Humans Immune response Immune system Lymphocytes T Male Medicine Medicine & Public Health Metabolic Diseases Neoplasm Staging Original Article Polymerase Chain Reaction Polymorphism, Genetic - genetics Polymorphism, Restriction Fragment Length Prognosis Programmed Cell Death 1 Receptor - blood Programmed Cell Death 1 Receptor - genetics Thyroid Neoplasms - blood Thyroid Neoplasms - genetics Thyroid Neoplasms - pathology |
| title | Association of PDCD1 gene markers with susceptibility to thyroid cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T19%3A56%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20PDCD1%20gene%20markers%20with%20susceptibility%20to%20thyroid%20cancer&rft.jtitle=Journal%20of%20endocrinological%20investigation&rft.au=Haghshenas,%20M.%20R.&rft.date=2017-05-01&rft.volume=40&rft.issue=5&rft.spage=481&rft.epage=486&rft.pages=481-486&rft.issn=1720-8386&rft.eissn=1720-8386&rft_id=info:doi/10.1007/s40618-016-0579-5&rft_dat=%3Cproquest_cross%3E1852661892%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1887063873&rft_id=info:pmid/27943063&rfr_iscdi=true |